Hematology NewsIbrutinib/buparlisib looks good for relapsed mantle cell lymphomaJune 27, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsPembrolizumab + rituximab boost response rates in relapsed follicular lymphomaJune 26, 2017Indolent LymphomaImmunotherapyLymphoma & Plasma Cell DisordersFollicular Lymphoma
Oncology PracticeCARs race for supremacy against aggressive non-Hodgkin lymphomaJune 25, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaFollicular Lymphoma
Hematology TimesNew SC rituximab formulation approved, reduces administration timeJune 24, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsTwofer drug blocks SYK/JAK pathways in advanced NHLJune 23, 2017CLLLymphoma & Plasma Cell DisordersAggressive LymphomasFollicular Lymphoma
Hematology TimesChemo-free triplet produces ‘favorable’ results in advanced diseaseJune 23, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsFDA approves rituximab + hyaluronidase human for FL, DLBCL, and CLLJune 22, 2017CLLAggressive LymphomasLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesInhibitor elicits responses in heavily pretreated FL, DLBCLJune 22, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsLenalidomide-rituximab induces high CR rate in untreated follicular lymphomaJune 21, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsGALEN safe and effective in relapsed and refractory follicular lymphomaJune 20, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesBiosimilar rituximab approved in EuropeJune 20, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesBLA for CAR T-cell therapy granted priority reviewMay 29, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesFDA grants priority review to NDA for copanlisibMay 18, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsSubcutaneous rituximab safe, effective for follicular lymphomaMay 9, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesDrug receives fast track designation for follicular lymphomaApril 26, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
